Healthcare

Healius (ASX:HLS) is one of Australia’s largest healthcare service providers, operating pathology and diagnostic imaging businesses. The company has faced significantEarningspressure due to healthcare funding constraints, rising labour costs and changing operating conditions, leading management to pursue restructuring initiatives and portfolio changes.

EMvision Medical Devices (ASX:EMV) is an Australian medical-technology company developing portable brain imaging systems designed to improve stroke diagnosis. Its technology aims to provide rapid imaging outside traditional hospital environments, including emergency departments and potentially pre-hospital settings. Investors are assessing the company’s clinical progress …

Clarity Pharmaceuticals (ASX:CU6) is an Australian clinical-stage biotechnology company developing targeted copper-based radiopharmaceutical treatments and imaging technologies. The company’s proprietary SAR technology platform aims to combine cancer diagnosis and therapy through its theranostic approach. Investors are assessing the potential of its oncology pipeline while …

Cambium Bio (ASX:CMB) is an Australian clinical-stage biotechnology company developing regenerative medicine therapies based on human platelet lysate technology. The company’s lead programs include Elate Ocular for dry eye disease and Progenza for tissue repair applications. Investors are assessing the potential of its clinical …

CLEO Diagnostics (ASX:COV) is a clinical-stage diagnostics company developing blood-based technology designed to assist in ovarian cancer detection and clinical decision-making. The company is progressing through regulatory and validation milestones in the United States, with potential commercial opportunities dependent on successful clinical outcomes and …

Aroa Biosurgery (ASX:ARX), a New Zealand-based medical technology company specialising in soft-tissue regeneration products, has reached an important stage in its development after achieving its first full-year statutory profit. The company is expanding its presence in the US medical market through products targeting surgical …

Australian Clinical Labs (ASX:ACL), one of Australia’s major pathology providers, has attracted investor attention after a period of share price weakness driven by statutory earnings pressure, costInflationand sector uncertainty. While reported profit declined due to one-off charges, the underlyingBusinessshowed improvement. Investors are assessing whether …